Gregory Korbel
Director de Operaciones en Atrin Pharmaceuticals, Inc. .
Perfil
Gregory A.
Korbel is currently the Chief Operating Officer at Atrin Pharmaceuticals, Inc. He previously worked as the Director of Research Operations at Johnson & Johnson.
From 2012 to 2015, he was the Director of Business Development & Operations at Novira Therapeutics LLC.
From 2022 to 2023, he was the Chief Operating Officer & Senior Vice President at Aprea Therapeutics, Inc. Korbel holds a doctorate from Harvard University, an undergraduate degree from Vanderbilt University, and an MBA from The Wharton School of the University of Pennsylvania.
Cargos activos de Gregory Korbel
| Empresas | Cargo | Inicio |
|---|---|---|
Atrin Pharmaceuticals, Inc.
 Atrin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Founded in 2012, Atrin Pharmaceuticals, Inc. is a DNA Damage Response development company that focuses on a pipeline of products resulting from a series of novel conformationally restricted macrocyclic molecules. Part of Aprea Therapeutics, Inc., the company is based in Doylestown, PA. Atrin Pharmaceuticals was acquired by Aprea Therapeutics, Inc. on May 16, 2022 for $1.33 million. The company's products have the highest known potency for inhibiting ATR and exhibit ATR selectivity with potential broad therapeutic profile. | Director de Operaciones | - |
Antiguos cargos conocidos de Gregory Korbel.
| Empresas | Cargo | Fin |
|---|---|---|
| APREA THERAPEUTICS, INC. | Director de Operaciones | 31/03/2023 |
Novira Therapeutics LLC
 Novira Therapeutics LLC Pharmaceuticals: MajorHealth Technology Novira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of therapies for the treatment of chronic hepatitis B (CHB) infection. The firm’s novel antiviral drug candidates addresses the limitations of CHB therapies. The company was founded in 2009 by Osvaldo Flores, Ali Munawar and George D. Hartman and is headquartered in Doylestown, PA. | Director de Operaciones | 01/12/2015 |
| JOHNSON & JOHNSON | Corporate Officer/Principal | - |
Formación de Gregory Korbel.
| Vanderbilt University | Undergraduate Degree |
| Harvard University | Doctorate Degree |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| APREA THERAPEUTICS, INC. | Health Technology |
| JOHNSON & JOHNSON | Health Technology |
| Empresas privadas | 2 |
|---|---|
Novira Therapeutics LLC
Novira Therapeutics LLC Pharmaceuticals: MajorHealth Technology Novira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of therapies for the treatment of chronic hepatitis B (CHB) infection. The firm’s novel antiviral drug candidates addresses the limitations of CHB therapies. The company was founded in 2009 by Osvaldo Flores, Ali Munawar and George D. Hartman and is headquartered in Doylestown, PA. | Health Technology |
Atrin Pharmaceuticals, Inc.
Atrin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Founded in 2012, Atrin Pharmaceuticals, Inc. is a DNA Damage Response development company that focuses on a pipeline of products resulting from a series of novel conformationally restricted macrocyclic molecules. Part of Aprea Therapeutics, Inc., the company is based in Doylestown, PA. Atrin Pharmaceuticals was acquired by Aprea Therapeutics, Inc. on May 16, 2022 for $1.33 million. The company's products have the highest known potency for inhibiting ATR and exhibit ATR selectivity with potential broad therapeutic profile. | Health Technology |
- Bolsa de valores
- Insiders
- Gregory Korbel
